Our oncology teams are finding breakthrough treatments to advance cancer care.
As one of 50 NCI designated comprehensive cancer centers in the country, our oncology program is helping patients beat the odds with comprehensive, multi-disciplinary care leveraging the latest in technology and novel therapies.
Oncology
In this 2022 review, read about NewYork-Presbyterian’s clinical and scientific advances in early cancer detection strategies and the acceleration of personalized therapeutics to achieve the best possible outcomes.
New Approaches Discovered to Enhance Immunotherapy to Treat Aggressive Form of B-Cell Lymphoma
Columbia oncologist finds that YF2, a first-in-class drug, modulates immune evasion and enhances the effects of immune checkpoint blockade in diffuse large B-cell lymphoma
A Breakthrough Radiotherapy Technique for Early Stage Breast Cancer Patients
NewYork-Presbyterian/Weill Cornell Medicine have developed a technique to treat early breast cancers with MRI-guided prone breast radiotherapy
Advancing the Early Detection of Pancreatic Cancer
At Columbia, Dr. Anil Rustgi presents insights into the current state of genetic testing, screening and surveillance with a goal to diagnose pancreatic cancer at a more treatable stage.
Targeted Therapy Shows Promise for Aggressive Uterine Sarcoma
Columbia oncologists led a phase 2 clinical trial demonstrating the potential of olaparib combined with chemotherapy to treat patients with uterine leiomyosarcoma, a rare and deadly form of uterine cancer.
Reason for Optimism: Advancing Therapy for Triple-Negative Breast Cancer
Columbia breast oncologist co-chairs Expert Panel to develop ASCO Guideline Rapid Recommendation Update on adding immunotherapy to neoadjuvant chemotherapy to treat TNBC.
Tumor Microenvironment of Lung Cancer: What Lies Beneath?
Weill Cornell Medicine investigators examine the role of the tumor microenvironment in the progression of precancerous non-solid nodules that appear on CT to invasive lung adenocarcinoma.
A Paradigm Shift in Radiation Treatment Planning
Columbia radiation oncologists are using a new radiation delivery system that leverages artificial intelligence to create a personalized plan in minutes and offers better cancer control while further reducing radiation side effects.
How Melanoma Prepares Lymph Nodes for Metastases
Weill Cornell Medicine cancer researchers uncover protein released in exosomes secreted by melanoma cells that leads to lymphangiogenesis.
Promising Treatment Emerges for Recurrent Glioblastoma
Columbia neuro-oncologist leads international phase 2 trial of selinexor, the first of a new class of anticancer drugs.
Lung Cancer: Testing a Novel Protocol
Combining immune checkpoint blockade and radiotherapy preoperatively is associated with a significant enhancement of major pathological response in the treatment of early-stage non-small-cell lung cancer.
New Understanding of B-Cell Cancers
Weill Cornell Medicine and Columbia University faculty at NewYork-Presbyterian Hospital have uncovered new information on the roles of the microenvironment and genomic architecture underlying the development and progression of B-cell and other malignancies.
Novel Approaches to Personalizing Cancer Therapy
Scientists at Columbia University and Weill Cornell Medicine are applying contemporary methods of data analysis to generate algorithms that narrow the number of genetic drivers involved in cancer development.
Accelerating Therapies for Challenging Blood Disorders
From studies in the laboratory to evaluating therapeutics in clinical trials, faculty at the NCI-designated Herbert Irving Comprehensive Cancer Center at Columbia University and the Weill Cornell Medicine Meyer Cancer Center in partnership with NewYork-Presbyterian are addressing the treatment challenges of blood disorders.
Prolonging Life for Men with Prostate Cancer
Extending survival was the focus of a recent multinational phase 3 clinical trial of a combination therapy for men with nonmetastatic, castration-resistant prostate cancer. Led by Weill Cornell Medicine Oncology, the study provides evidence that adding androgen-receptor inhibitors to current therapies delays metastasis and improves survival.
Non-Small Cell Lung Cancer: A New Combination for Neoadjuvant Therapy
A novel trial of chemotherapy combined with a PD-L1 inhibitor administered preoperatively in patients with resectable non-small cell lung cancer has had impressive results, raising expectations among oncologists and surgeons that they may soon have a new therapeutic strategy to offer patients with this life-threatening disease.
Novel Research Advancing Cancer Care and Treatment
Studies by Columbia University and Weill Cornell Medicine faculty are making headlines in oncology research, providing promising evidence for new therapies and better understanding of the origins of blood and solid tumor cancers.
Extending the Boundaries of Cancer Care
NewYork-Presbyterian/
Exceptional Expertise in Rare Cancers
Combined rare cancers account for 50% of all cancer diagnoses. Researchers at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/
Investigating Immunotherapy Approaches in Genitourinary Oncology
Dr. Charles G. Drake initiated a cutting-edge trial in which androgen deprivation therapy is combined with a drug aimed at preventing suppressive myeloid cells from entering the prostate tumor microenvironment at the time of therapy.
A New Take on BMT and Cellular Therapies
As the Adult Blood and Marrow Transplant Program at NewYork-Presbyterian/
Confronting Solid Tumors: Vitamin C Takes on the KRAS Gene
With a multimillion dollar grant, investigators at NewYork-Presbyterian/
Neoadjuvant Therapy in Breast Cancer: A New Raison D’être
In the past 50 years, use of neoadjuvant chemotherapy for breast cancer has evolved. Today, clinicians at NewYork-Presbyterian are using neoadjuvant therapy to tackle residual tumor.
Targeting Early Breast Cancers with Ablation Therapies
Surgeons at NewYork-Presbyterian/
Newsletters for Medical Professionals
2023 Issue 2
- A Breakthrough Radiotherapy Technique for Early Stage Breast Cancer Patients
- Advancing the Early Detection of Pancreatic Cancer
2023 Issue 1
- Tumor Microenvironment of Lung Cancer: What Lies Beneath?
- Targeted Therapy Shows Promise for Aggressive Uterine Sarcoma
2022 Issue 1
- Promising Treatment Emerges for Recurrent Glioblastoma
- How Melanoma Prepares Lymph Nodes for Metastases
2021 Issue 3
2021 Issue 2
2021 Issue 1
- Shared Decision-Making: A Critical Adjunct to Prostate Cancer Care
- Advancing the Prostate Cancer Care Paradigm
- Herbert Irving Comprehensive Cancer Center Earns National Cancer Institute Renewal
2020 Issue 1
- Patient-Derived Organoids: Continuing a Promise of Progress in Cancer Therapeutics
- Awards and Honors
2019 Issue 2
- Renowned GI Physician-Scientists Lead Cancer Care and Research Programs at NewYork-Presbyterian
2019 Issue 1
- Open Surgery Safer than Minimally Invasive Approach for Early-Stage Cervical Cancer
- Regulating Metabolism in the Setting of Cancer
2018 Issue 3
- Noted Breast Surgeon Appointed Chief of Breast Surgery at Weill Cornell
- A New Take on BMT and Cellular Therapies
- Weill Cornell Medicine Faculty Win NCI Outstanding Investigator Awards
2018 Issue 2
- 2018 Young Investigator Awards: Recognizing Up and Coming Scientists
- Confronting Solid Tumors: Vitamin C Takes on the KRAS Gene
2018 Issue 1
- Prestigious SPORE Grant to Advance Prostate Cancer Care
- Renowned Surgeon Leads Columbia Breast Surgery Program
- Comprehensive Programs Address Brain and CNS Metastases
- NewYork-Presbyterian Establishes the William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma
2017 Issue 2
- Targeting Early Breast Cancers with Ablation Therapies
- Neoadjuvant Therapy in Breast Cancer: A New Raison D’être
- Ongoing Research in Early-Stage Invasive Breast Cancer Treatment
- Weill Cornell Medicine Awarded SPORE Grant in Prostate Cancer
2017 Issue 1
- Ovarian Cancer: Overcoming Obstacles to Immunotherapy
- Immunotherapy: A New Frontier in Genitourinary Cancers